Celyad Oncology SA
| NASDAQ: CYAD |
| Healthcare / Biotechnology / Belgium |
| 4.26 | -0.3200 | -6.99% | Vol 24.63K | 1Y Perf -56.85% |
| Jul 27th, 2021 13:13 DELAYED |
| BID | 4.25 | ASK | 4.43 | ||
| Open | 4.38 | Previous Close | 4.58 | ||
| Pre-Market | 4.37 | After-Market | - | ||
| -0.21 -4.59% | - - |
| Target Price | 17.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 285.49 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 42.00 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★+ 43.06 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 66.00M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 3.64 | Earnings Date | 24th Mar 2021 |
Today's Price Range 4.264.41 | 52W Range 4.0110.87 | 5 Year PE Ratio Range -6.70-5.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 9.83% | ||
| 1 Month | -16.12% | ||
| 3 Months | -27.65% | ||
| 6 Months | -43.67% | ||
| 1 Year | -56.85% | ||
| 3 Years | -85.13% | ||
| 5 Years | -81.23% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -52.52 | |||
ROE last 12 Months | -73.04 | |||
ROA (5Y Avg) | -42.98 | |||
ROA last 12 Months | -34.10 | |||
ROC (5Y Avg) | -48.46 | |||
ROC last 12 Months | -72.58 | |||
Return on invested Capital Q | -27.70 | |||
Return on invested Capital Y | -40.08 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.90 | ||||
| 2.09 | ||||
| 161.56K | ||||
| - | ||||
| -3.60 | ||||
| -2.34 | ||||
| 2.11 | ||||
| 1.99 | ||||
| 60.38M | ||||
| Forward PE | -3.07 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.20 | ||||
| 1.40 | ||||
| 0.08 | ||||
| 0.13 | ||||
| -70.40 | ||||
| Leverage Ratio | 2.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 100.00 | ||||
| -263 946.00 | ||||
| -247 654.00 | ||||
| -111 680.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 445.00 | ||||
| 0.00 | ||||
| -87.15 | ||||
| 67.90 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2019 QR | -1.58 | 10.73 | Positive |
| 12/2019 QR | -1.65 | -0.61 | Negative |
| 12/2021 FY | -1.83 | 2.14 | Positive |
| 12/2022 FY | -1.51 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 24.63K |
| Shares Outstanding | 15.49M |
| Trades Count | 98 |
| Dollar Volume | 95.93K |
| Avg. Volume | 38.99K |
| Avg. Weekly Volume | 48.71K |
| Avg. Monthly Volume | 40.21K |
| Avg. Quarterly Volume | 64.85K |
Celyad Oncology SA (NASDAQ: CYAD) stock closed at 4.58 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 33.30K shares and market capitalization of 66.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Celyad Oncology SA CEO is Filippo Petti.
The one-year performance of Celyad Oncology SA stock is -56.85%, while year-to-date (YTD) performance is -41.28%. CYAD stock has a five-year performance of -81.23%. Its 52-week range is between 4.01 and 10.87, which gives CYAD stock a 52-week price range ratio of 3.64%
Celyad Oncology SA currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 2.09, a price-to-sale (PS) ratio of 161 555.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.10%, a ROC of -72.58% and a ROE of -73.04%. The company’s profit margin is -%, its EBITDA margin is -247 654.00%, and its revenue ttm is $445.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Celyad Oncology SA, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Celyad Oncology SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for Celyad Oncology SA is Strong Buy (1), with a target price of $17, which is +285.49% compared to the current price. The earnings rating for Celyad Oncology SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Celyad Oncology SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Celyad Oncology SA has a Sell technical analysis rating based on Technical Indicators (ADX : 11.20, ATR14 : 0.27, CCI20 : -33.99, Chaikin Money Flow : -0.11, MACD : -0.26, Money Flow Index : 41.66, ROC : -2.76, RSI : 42.87, STOCH (14,3) : 53.77, STOCH RSI : 0.93, UO : 52.39, Williams %R : -46.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Celyad Oncology SA in the last 12-months were:
Celyad Oncology SA
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
CEO: Filippo Petti
Telephone: +32 10394100
Address: Rue Edouard Belin 2, Mont-Saint-Guibert 1435, , BE
Number of employees: 107
